6-propionyl-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine | 94662-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-propionyl-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine
• 英文别名: 6-propionyl-2-methyl-1,4-benzoxazin-3-(4H)-one；2-methyl-6-propanoyl-4H-1,4-benzoxazin-3-one
• CAS: 94662-47-2
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: BHUDGKMZGRHXQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-propionyl-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 在 盐酸 、 乙酸酐 、 肼 作用下， 以 甲醇 、 乙醇 、 水 、 丙酮 为溶剂， 反应 4.5h， 生成 2-Methyl-6-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-4H-benzo[1,4]oxazin-3-one
  参考文献：
  名称：

  6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents

  摘要：

  A series of 6-benzoxazinylpyridazin-3-ones was prepared and evaluated for inhibition of cardiac phosphodiesterase (PDE) fraction III in vitro and for positive inotropic activity in vivo. 6-[3,4-Dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl]-2,3,4,5-tetrahydro-5 - methylpyridazin-3-one (bemoradan) was found to be an extremely potent and selective inhibitor of canine PDE fraction III and a long-acting, potent, orally active inotropic vasodilator agent in various canine models. Additional benzoxazin-6-yl and -8-yl compounds were also prepared. Altering the pyridazinone substitution from the 6-position to the 7-position produced a 14-fold increase in the iv cardiotonic potency (ED50) from 77 to 5.4 micrograms/kg while substitution at the 8-position reduced potency. Methyl substitution at various sites in the molecule was also examined. Positive inotropic activity was maintained for between 8 and 24 h after a single oral dose (100 micrograms/kg) of bemoradan in dogs, thus making it one of the most potent and long-acting orally effective inotropes yet described. Bemoradan is currently under development as a cardiotonic agent for use in the management of congestive heart failure.

  DOI：

  10.1021/jm00163a061
• 作为产物：
  描述：

  2-氨基苯酚 在 三氯化铝 、 碳酸氢钠 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 6-propionyl-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine
  参考文献：
  名称：

  6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents

  摘要：

  A series of 6-benzoxazinylpyridazin-3-ones was prepared and evaluated for inhibition of cardiac phosphodiesterase (PDE) fraction III in vitro and for positive inotropic activity in vivo. 6-[3,4-Dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl]-2,3,4,5-tetrahydro-5 - methylpyridazin-3-one (bemoradan) was found to be an extremely potent and selective inhibitor of canine PDE fraction III and a long-acting, potent, orally active inotropic vasodilator agent in various canine models. Additional benzoxazin-6-yl and -8-yl compounds were also prepared. Altering the pyridazinone substitution from the 6-position to the 7-position produced a 14-fold increase in the iv cardiotonic potency (ED50) from 77 to 5.4 micrograms/kg while substitution at the 8-position reduced potency. Methyl substitution at various sites in the molecule was also examined. Positive inotropic activity was maintained for between 8 and 24 h after a single oral dose (100 micrograms/kg) of bemoradan in dogs, thus making it one of the most potent and long-acting orally effective inotropes yet described. Bemoradan is currently under development as a cardiotonic agent for use in the management of congestive heart failure.

  DOI：

  10.1021/jm00163a061

文献信息

• Imidazo-heterocyclic compounds and pharmaceutical composition comprising
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04621084A1

  公开（公告）日：1986-11-04

  New imidazo-heterocyclic compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl or halogen, R.sup.2 is hydrogen, lower alkyl, halogen, aminomethyl optionally substituted with lower alkyl, or piperazin-1-yl-methyl optionally substituted with lower alkyl, R.sup.3 is a partially suturated heterocyclic group selected from benzothiazolinyl, benzoxazolinyl, benzimidazolinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl and 1,2,3,4-tetrahydroquinoxalinyl, which is substituted with oxo, thioxo, imino or lower alkylimino, and which may be substituted with lower alkyl optionally substituted with lower alkanoyloxy, lower alkoxycarbonyl, pyridyl or lower alkylamino; or an unsaturated heterocyclic group selected from benzoxazolyl and benzimidazolyl, which may be substituted with lower alkyl or pyridyl(lower)alkylthio, and Y is .dbd.N-- or a group of the formula: ##STR2## in which R.sup.4 is hydrogen, hydroxy, lower alkyl, lower alkoxy or ar(lower)alkoxy, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and pharmaceutically acceptable salts thereof are useful as cardiotonic agents and untiulcer agents.

  新的咪唑-杂环化合物的化学式翻译如下：其中R.sup.1为氢、较低的烷基或卤素，R.sup.2为氢、较低的烷基、卤素、氨甲基（可选择性地取代为较低的烷基）或哌嗪-1-基甲基（可选择性地取代为较低的烷基），R.sup.3为从苯并噻唑基、苯并噁唑基、苯并咪唑基、3,4-二氢-2H-1,4-苯并噻唑基、3,4-二氢-2H-1,4-苯并噁唑基和1,2,3,4-四氢喹喔啉基中选择的部分饱和杂环基，该基取代为氧代、硫代、亚胺或较低的烷基亚胺，并且可以取代为可选择性地取代为较低的烷基、可选择性地取代为较低的烷酰氧基、较低的烷氧羰基、吡啶基或较低的烷基氨基；或从苯并噁唑基和苯并咪唑基中选择的不饱和杂环基，该基可以取代为较低的烷基或吡啶基（较低）烷基硫基，Y为.dbd.N--或化学式的一个基团：其中R.sup.4为氢、羟基、较低的烷基、较低的烷氧基或芳基（较低）烷氧基，以及其药学上可接受的盐，以及其制备方法和包含它们的药物组合物。这些衍生物及其药学上可接受的盐可用作心力衰竭药物和抗溃疡药物。
• Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals
  申请人：Schering Aktiengesellschaft

  公开号：US06365736B1

  公开（公告）日：2002-04-02

  Described are benzoxazine and benzothiazine compounds of the formula I defined herein, methods for their preparation and methods for their use in pharmaceuticals based on their activity as NO-synthases (NOS) inhibitors.

  本文描述了我在此定义的式I的苯并噁嗪和苯并噻嗪化合物，以及它们的制备方法和基于它们作为一氧化氮合酶（NOS）抑制剂的药物使用方法。
• [DE] BENZOXAZIN- UND BENZOTHIAZIN-DERIVATE UND DEREN VERWENDUNG IN ARZNEIMITTELN<br/>[EN] BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS<br/>[FR] DERIVES DE BENZOXAZINE ET DE BENZOTHIAZINE ET LEUR UTILISATION DANS DES MEDICAMENTS
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：WO1999012915A1

  公开（公告）日：1999-03-18

  (DE) Es werden Verbindungen der Formel (I) beschrieben sowie deren Herstellung und Verwendung in Arzneimitteln.(EN) The invention relates to compounds of the formula formula (I) and to their production and their use in pharmaceuticals.(FR) La présente invention concerne des composés correspondant à la formule (I), ainsi que leur production et leur utilisation dans des médicaments.

  (德语)根据本发明，涉及具有表式(I)化合物及其制备方法及在药物中的应用。(英文)本发明涉及公式(I)的化合物及其制备和在药物中的应用。(法语)LLEGAL穿越者发明涉及对应化工业园区(Capteur de Traction)的目标部分… 把本发明结合到一个实际应用中，将有助于实现这一目标。
• Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0120589B1

  公开（公告）日：1988-06-08
• BENZOXAZIN- UND BENZOTHIAZIN-DERIVATE UND DEREN VERWENDUNG IN ARZNEIMITTELN
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP1015437B1

  公开（公告）日：2003-12-03